kedrion.comCrawled Nov 9, 2026
Kedrion operates four state-of-the-art manufacturing facilities in Italy, Hungary, and the United States.
Kedrion provides medical information about its products and related disorders.
Kedrion’s Global Quality Assurance program ensures company-wide quality standards.
“Donating is part of my life,” observes Heinz Kühlein. And he means it: Heinz has been donating blood or blood plasma since 1970, when he was doing his army service. Ten years later he was donating at the Bavarian Red Cross in Bayreuth and that is where he meet Angela Beck, who was working there.
Kedrion’s research and development team developed potential COVID-19 therapies using convalescent plasma from recovered patients.
Pier Mannuccio Mannucci presented the SIPPET Study at the 8th BIC – Bari International Conference in 2014.
2018 marks the 50th anniversary of the discovery of Anti-D Immunoglobulins for the prevention of Rh sensitization during pregnancy.
A campaign that focuses on people around the world who are living with rare diseases and rely on the availability of plasma therapies.
· information and IT assistance companies
Kedrion’s commitment to the welfare of its employees goes beyond health and safety.
Kedrion recruits bright and enthusiastic colleagues to join its team.
Kedrion maintains high health and safety standards for plasma collection and distribution.
Located 15 kilometers from Naples, in Campania Region, the Sant’Antimo plant has been part of Kedrion since its foundation in 2001. With an area of approximately 40,000 m², the site specializes in the production of hyperimmune immunoglobulins and virus-inactivated.
Kedrion advocates for self-sufficiency in plasma collection for communities and countries.
Kedrion’s plasma-derived therapies help people suffering from debilitating conditions like Hemophilia and Immune Deficiencies.
INFORMATION pursuant to Articles 13 and 14 of EU Regulation 679/2016 and the Privacy Code as amended by Legislative Decree 101/2018, regarding Pharmacovigilance
